Previous close | 12.74 |
Open | 13.39 |
Bid | 11.93 x 200 |
Ask | 13.72 x 200 |
Day's range | 12.17 - 13.45 |
52-week range | 10.87 - 83.60 |
Volume | |
Avg. volume | 1,289,957 |
Market cap | 1.375B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.95 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.33 |
Comprehensive Analysis of NovoCure's First Quarter Financial Performance
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s